Research out of the Netherlands suggests current clinical guidelines might recommend overtreatment for women with heart failure, who see maximum benefit from HF drugs at half the dose of men.

SGLT2 inhibitors—namely dapagliflozin—have been linked to a reduced risk of heart failure and death, as well as decreased odds of major adverse cardiovascular events.

Oregon Health & Science University will resume its heart transplant services this month after nearly a year of inactivity, the university announced Aug. 26.

Managing new-onset HF is a delicate task for cardiologists, and one that demands an appropriate balance between aggressive treatment and optimal quality of life for the patient. But that balance may be harder to strike than previously thought, researchers reported in Circulation this month.

Istaroxime, a dual action, luso-inotropic agent that’s still in clinical development, was granted fast-track designation by the FDA this month as a possible treatment for HFrEF.

The FDA on August 16 granted breakthrough designation to CVRx Inc.’s Barostim Neo System, a device meant to improve heart failure symptoms in patients unsuited for other therapies like CRT. 

Biopharmaceutical company Renovacor, Inc., on August 14 announced it had raised $11 million in Series A financing to further develop its gene therapy-based treatments for CVD.

Swiss drugmaker Novartis on July 29 announced its combo sacubitril/valsartan drug Entresto “narrowly missed” its primary endpoint in the Phase III PARAGON-HF study, throwing into question the future of a blockbuster drug.